NDA 218158 · Harrow Eye
Byqlovi
Clobetasol Propionate · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Apr 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 4, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
119
23 Phase 3, 10 recruiting
FAERS reports
10,595
4,972 serious, 439 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 26, 2026.
BYQLOVI is indicated for the treatment of post-operative inflammation and pain following ocular surgery. BYQLOVI is a corticosteroid indicated for the treatment of post- operative inflammation and pain following ocular surgery. ( 1 )
Mechanism: Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BYQLOVI · CLOBETASOL PROPIONATE 0.05% · SUSPENSION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clobetasol Propionate" as an intervention, any sponsor and status, largest first.
Beni-Suef UniversityAcademic, hospital or other
NCT03878771 · 804 participants · Start Mar 13, 2019 · Primary completion Apr 15, 2019
Drug: Platelet rich fibrin gel in Orabase; Dermovate cream in Orabase · For: Oral Ulcer Due to Pemphius Vularis; Oral Ulcer Due to Benign Mucous Membrane Pemphioid; Oral Ulcer Due to Steven Johnson's Syndrome
Sites: Banī Suwayf, Egypt
- Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01235442 · 592 participants · Start Sep 2010 · Primary completion Oct 2011
Drug: 1=Etanercept; 2=Clobetasol propionate foam · For: Psoriasis
- Silver Nitrate Versus Topical Steroid For Umbilical GranulomaPivotal-lookingCompleted
Children Hospital and Institute of Child Health, LahoreAcademic, hospital or other
NCT06363539 · 354 participants · Start Sep 20, 2022 · Primary completion Mar 20, 2023
Drug: Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION; Silver Nitrate · For: Umbilical Granuloma
Sites: Lahore, Pakistan
- Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic DermatitisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00862654 · 326 participants · Start Mar 2009 · Primary completion Feb 2010
Drug: clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week); clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week) and 2 more · For: Scalp Seborrheic Dermatitis
Sites: Bruges, Belgium; Brussels, Belgium; Geel, Belgium · 18 sites in all
- Topical Steroids Alone or Associated With Methotrexate in Bullous PemphigoidPivotal-lookingCompleted
University Hospital, MontpellierAcademic, hospital or other
NCT02313870 · 322 participants · Start Jan 22, 2008 · Primary completion May 26, 2015
Drug: clobetasol propionate + Methotrexate; clobetasol propionate alone · For: Bullous Pemphigoid
Sites: Montpellier, France
- Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01313221 · 310 participants · Start Apr 2011 · Primary completion Dec 2012
Drug: etanercept; Topical agents · For: Psoriasis
Sites: Calgary, Canada; Surrey, Canada; Vancouver, Canada · 24 sites in all
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06120140 · 305 participants · Start Feb 16, 2024 · Primary completion May 31, 2027
Drug: Amivantamab IV; Amivantamab SC and 9 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Chandler, Arizona; Duarte, California; Fullerton, California · 93 sites in all
- Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque PsoriasisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00658788 · 305 participants · Start Mar 2008 · Primary completion Jan 2009
Drug: clobetasol propionate spray 0.05%; calcitriol ointment · For: Psoriasis
Sites: San Diego, California; Newnan, Georgia; Snellville, Georgia · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,087
- pruritus983
- off label use682
- rash676
- product use in unapproved indication553
- psoriasis550
- fatigue531
- headache501
- diarrhoea448
- nausea441
- dry skin423
- arthralgia421
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 20 |
| 2006 | 58 |
| 2007 | 92 |
| 2008 | 95 |
| 2009 | 125 |
| 2010 | 135 |
| 2011 | 215 |
| 2012 | 318 |
| 2013 | 162 |
| 2014 | 185 |
| 2015 | 346 |
| 2016 | 403 |
| 2017 | 536 |
| 2018 | 459 |
| 2019 | 471 |
| 2020 | 558 |
| 2021 | 604 |
| 2022 | 920 |
| 2023 | 1,216 |
| 2024 | 1,152 |
| 2025 | 1,320 |
| 2026 | 1,188 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of oral lichen planus. Systematic review and therapeutic guide.
García-Pola MJ, González-Álvarez L, Garcia-Martin JM · Med Clin (Barc) 2017 · Systematic Review
- double-blind"double-bind.
Björnberg A, Hellgren L · Curr Med Res Opin 1975 · Clinical Trial, Comparative Study
- Seborrhoeic dermatitis.
Naldi L · BMJ Clin Evid 2010 · Systematic Review
- Seborrhoeic dermatitis.
Manríquez JJ, Uribe P · BMJ Clin Evid 2007 · Systematic Review
- Interventions for treating oral lichen planus: corticosteroid therapies.
Lodi G, Manfredi M, Mercadante V, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Platelet-rich fibrin a new approach in management of persistent oral ulcers in blistering skin diseases.
Ahmed EM, Shafik S, El Saadany B · Wound Repair Regen 2022 · Randomized Controlled Trial
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.